Editas Medicine (NASDAQ:EDIT) Share Price Passes Below Fifty Day Moving Average - What's Next?Market Beat·Jul 17 at 02:40 AMEDIT+3.08%
The Biotech Survival Curve: How Milestone Checks and In-Vivo CRISPR Are Rewriting the RulesGlobal Report·Jul 4 at 04:01 AMPRTA-0.57%EDIT+3.08%
Editas Medicine shareholders elect Connaughton, Levy as Class I directors at annual meetingPUBT·Jun 18 at 03:29 PMEDIT+3.08%
EDIT: Director elections, compensation, and auditor ratification passed; EDIT-401 clinical plans advancedQuartr·Jun 17 at 08:28 AMEDIT+3.08%
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?nasdaq·May 31 at 12:10 PMCRSP+0.41%EDIT+3.08%
Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVXrttnews·May 28 at 03:13 AMQTTB+0.40%EDIT+3.08%
Editas Medicine Announces Proposed Public Offering | EDIT Stock NewsStockTitan·May 25 at 09:15 PMEDIT+3.08%LABU+0.27%
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering | EDIT Stock NewsStockTitan·May 26 at 12:05 AMEDIT+3.08%IBB+0.10%
